ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE INJECTION SOLUTION

Land: Canada

Språk: engelsk

Kilde: Health Canada

Aktiv ingrediens:

ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

Tilgjengelig fra:

PIERREL S.P.A.

ATC-kode:

N01BB58

INN (International Name):

ARTICAINE, COMBINATIONS

Dosering :

40MG; 0.009MG

Legemiddelform:

SOLUTION

Sammensetning:

ARTICAINE HYDROCHLORIDE 40MG; EPINEPHRINE BITARTRATE 0.009MG

Administreringsrute:

BLOCK/INFILTRATION

Enheter i pakken:

50X1.7ML

Resept typen:

Ethical

Terapeutisk område:

LOCAL ANESTHETICS

Produkt oppsummering:

Active ingredient group (AIG) number: 0252683001; AHFS:

Autorisasjon status:

APPROVED

Autorisasjon dato:

2018-04-17

Preparatomtale

Articaine Hydrochloride and Epinephrine Bitartrate Injection
Page 1
PRODUCT
MONOGRAPH
ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE INJECTION
40 MG/ML / 0.009 MG/ML (EPINEPHRINE 1:200,000)
AND
ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE INJECTION
40 MG/ML / 0.018 MG/ML (EPINEPHRINE 1:100,000)
LOCAL ANAESTHETIC FOR DENTAL USE
PIERREL S.P.A. DATE OF PREPARATION :
CAPUA (CE) JAN 23, 2023
ITALY 81043
IMPORTED BY :
INNOMAR STRATEGIES INC.
OAKVILLE, ONTARIO
L6L 0C4
DISTRIBUTED BY:
SINCLAIR DENTAL CO. LTD.
VANCOUVER, BC
V7P 3T8
CONTROL NUMBER: 270990
Articaine Hydrochloride and Epinephrine Bitartrate Injection
Page 2
TABLE OF CONTENTS
TABLE OF
CONTENTS...........................................................................................................
2
CLINICAL PHARMACOLOGY
..............................................................................................
3
INDICATIONS AND CLINICAL USE
....................................................................................
3
CONTRAINDICATIONS
.........................................................................................................
4
WARNINGS
..............................................................................................................................
4
PRECAUTIONS
........................................................................................................................
4
ADVERSE REACTIONS
.........................................................................................................
6
SYMPTOMS AND TREATMENT OF OVERDOSAGE
........................................................ 6
DOSAGE AND ADMINISTRATION
......................................................................................
7
PHARMACEUTICAL INFORMATION
..................................................................................
8
AVAILABILITY OF DOSAGE FORMS
.................................................................................
9
PHARMACOLOGY
................................................................